Patents by Inventor Barrett Allan
Barrett Allan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11623956Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.Type: GrantFiled: February 22, 2021Date of Patent: April 11, 2023Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
-
Publication number: 20210269520Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.Type: ApplicationFiled: February 22, 2021Publication date: September 2, 2021Inventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
-
Publication number: 20190031748Abstract: The present invention relates to antibodies that bind to human CGRP, compositions and kits comprising such CGRP antibodies, and methods of using such CGRP antibodies for detection of human CGRP.Type: ApplicationFiled: January 20, 2017Publication date: January 31, 2019Inventors: Xiyun CHAI, Barrett ALLAN
-
Publication number: 20180291093Abstract: Bispecific antibodies are provided that bind Calcitonin Gene Related Peptide (CGRP) and Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CGRP and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Psoriatic Arthritis (PsA) and ankylosing spondylitis (AS).Type: ApplicationFiled: October 30, 2015Publication date: October 11, 2018Applicant: Eli Lilly and CompanyInventors: Robert Jan Benschop, Rohn L Millican, JR., Barrett Allan, Catherine Brautigam Beidler
-
Patent number: 9951146Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.Type: GrantFiled: March 24, 2016Date of Patent: April 24, 2018Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Kristine Kay Kikly, Derrick Ryan Witcher
-
Patent number: 9708402Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: GrantFiled: May 18, 2016Date of Patent: July 18, 2017Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
-
Publication number: 20170073403Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: ApplicationFiled: November 2, 2016Publication date: March 16, 2017Applicant: Eli Lilly and CompanyInventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
-
Patent number: 9505838Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: GrantFiled: June 4, 2015Date of Patent: November 29, 2016Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
-
Publication number: 20160289342Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.Type: ApplicationFiled: March 24, 2016Publication date: October 6, 2016Inventors: Barrett Allan, Kristine Kay Kikly, Derrick Ryan Witcher
-
Publication number: 20160251430Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: ApplicationFiled: May 18, 2016Publication date: September 1, 2016Applicant: Eli Lilly and CompanyInventors: Barrett ALLAN, Robert Jan BENSCHOP, Jirong LU
-
Patent number: 9416182Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).Type: GrantFiled: March 4, 2014Date of Patent: August 16, 2016Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
-
Patent number: 9359448Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: GrantFiled: April 16, 2013Date of Patent: June 7, 2016Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
-
Patent number: 9328173Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.Type: GrantFiled: December 17, 2014Date of Patent: May 3, 2016Assignee: Eli Lilly and CompanyInventors: Hector Aldaz, Barrett Allan, Ling Liu, Jirong Lu, Ying Tang, Sheng-Hung Rainbow Tschang, Pia Pauliina Yachi
-
Publication number: 20150259415Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: ApplicationFiled: June 4, 2015Publication date: September 17, 2015Applicant: ELI LILLY AND COMPANYInventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
-
Patent number: 9073991Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.Type: GrantFiled: June 7, 2011Date of Patent: July 7, 2015Assignee: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
-
Publication number: 20150175708Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.Type: ApplicationFiled: December 17, 2014Publication date: June 25, 2015Inventors: Hector ALDAZ, Barrett ALLAN, Ling LIU, Jirong LU, Ying TANG, Sheng-Hung Rainbow TSCHANG, Pia Pauliina YACHI
-
Publication number: 20140255406Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).Type: ApplicationFiled: March 4, 2014Publication date: September 11, 2014Applicant: Eli Lilly and CompanyInventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
-
Publication number: 20130280256Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).Type: ApplicationFiled: April 16, 2013Publication date: October 24, 2013Applicant: Eli Lilly and CompanyInventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
-
Patent number: 8530414Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.Type: GrantFiled: September 12, 2012Date of Patent: September 10, 2013Assignee: Eli Lilly and CompanyInventors: Julian Davies, Ryan James Darling, Barrett Allan
-
Publication number: 20130071405Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.Type: ApplicationFiled: September 12, 2012Publication date: March 21, 2013Applicant: ELI LILLY AND COMPANYInventors: Julian Davies, Ryan James Darling, Barrett Allan